Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Blueprint Medicines Corp shares valued at $510,000 were purchased by Albers Jeffrey W. on Nov 07 ’24. At $102.00 per share, Albers Jeffrey W. acquired 5,000 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Namouni Fouad sold 3,633 shares, netting a total of over 324,500 in proceeds. Following the sale of shares at $89.32 each, the insider now holds 69,070 shares.
Before that, Albers Jeffrey W. had sold 19,702 shares from its account. In a trade valued at $1,685,891, the Director traded Blueprint Medicines Corp shares for $85.57 each. Upon closing the transaction, the insider’s holdings decreased to 19,702 shares, worth approximately $15.97 million.
As published in their initiating research note from UBS on October 24, 2024, Blueprint Medicines Corp [BPMC] has been a Neutral and the price target has been revised to $88. Analysts at Stephens started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid May. As of May 06, 2024, Leerink Partners has increased its “an Underperform” rating to a “Market perform” for BPMC. Earlier on October 27, 2023, Oppenheimer upgraded its rating. Their new recommendation was “an Outperform” for BPMC stock which previously was a “a Perform”.
Analyzing BPMC Stock Performance
During the last five days, there has been a surge of approximately 15.86%. Over the course of the year, Blueprint Medicines Corp shares have jumped approximately 9.92%. Shares of the company reached a 52-week high of $121.90 on 07/16/24 and a 52-week low of $72.24 on 02/14/24. A 50-day SMA is recorded $89.07, while a 200-day SMA reached $95.22. Nevertheless, trading volume fell to 0.7 million shares from 0.97 million shares the previous day.
Support And Resistance Levels for Blueprint Medicines Corp (BPMC)
According to the 24-hour chart, there is a support level at 99.17, which, if violated, would cause prices to drop to 96.94. In the upper region, resistance lies at 103.04. The next price resistance is at 104.69. RSI (Relative Strength Index) is 73.09 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 10.52, which suggests the price will increase in the coming days. Percent R is at 4.93%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
